Observation Of The Efficacy Of Niubei Blood Stasis-removing And Phlegm Eliminating Prescription's Treatment For Ankylosing Spondylitis'phlegm-blood Stasis Syndrome

ObjectivesBy comparing and analysis before and after treatment of AS'phlegm-blood stasis syndrome,Bath Ankylosing Spondylitis Disease Activity Index(BASDAI),spinal pain VAS and global evaluation VAS(0-10cm)scores,laboratory indicators,etc,evaluate clinical efficacy and safety of Niubei Blood stasis-removing and Phlegm eliminating prescription's Treatment for phlegm-blood stasis syndrome of AS,to provide a reliable basis for Clinical use of the prescription.MethodsBased on randomized method,according to the inclusion criteria,66 patients were divided into treatment group and the control group.At last,treatment group 32 cases,detached 1 cases and control group 31 cases,detached 2 cases.The control group was given Sulfasalazine enteric-coated tablets and Loxoprofen sodium tablets,the treatment group was given Niubei Blood stasis-removing and Phlegm eliminating prescription's Treatment based on the control group.The patients are asked to strengthen the physical exercise,maintain good posture to avoid excessive fatigue.The observation time is 2 month.Use the statistical software SPSS24.0 editions to analysis data and assess clinical treatment results.Results1 Comparison of the baseline of the two groupsIn distribution,the patient's age,sex,course,symptoms,BASDAI,spine VAS scores and PGA scores,and laboratory parameters between the two groups showed no significant difference in statistics(P>0.05),which indicates the two groups are comparable.2 Comparison of the clinical efficacy of treatment in both groupsTCM syndromes:The total effective rate of treatment group was 84.39%,the control group was 58.07%,The difference were statistically significant between the two groups(p<0.05).3 Comparison of Symptom scores in both groupsThe difference between the value of the treament group after treatment were statistically significant(p<0.05).The difference between the value of the control group after treatment were statistically significant(p<0.05)on lumbosacral pain,back pain,lumbar spinal activity limitation,noctumal pain,morning stiffness,peripheral joint swelling areas.But the difference were no statistically significant(P>0.05)on purple skin,feeling of heaviness and soreness and weakness of the lumbar region areas.The difference between the two groups were statistically significant(p<0.05)on lumbosacral pain,back pain,lumbar spinal activity limitation,nocturnal pain,peripheral joint swelling,purple skin,soreness and weakness of the lumbar region areas,but no statistically significant(p>0.05)on morning stiffness,feeling of heaviness areas.4 Comparison of BASDAI,spine VAS score,PGA score in both groupsThe difference between the treament group and the control group in BASDAI,spine VAS score,PGA score and score in same group before and after treatment were tistically significant(p<0.05).5 Comparison of laboratory parameters in both groupsThe difference between the treament group and the control group in ESR,CRP and score in same group before and after treatment were tistically significant(P<0.05).6 Comparison of safetyTreatment groups,there are 1 patient with gastrointestinal discomfort,and in the control group,there are 1 patients with gastrointestinal discomfort,and 1 patient with abnormal liver-function.Through symptomatic treatment,all symptoms are improved.The routine blood and urine tests,liver functions,liver-function of both groups were within the normal range.ConclusionsTreatment of Blood stasis-removing and Phlegm eliminating joint Sulfasalazine enteric-coated tablets and Loxoprofen sodium tablets,and Treatment of Sulfasalazine enteric-coated tablets joint Loxoprofen sodium tablets,can make the symptoms,signs,spine function improved,inflammation indicators reduced and the disease delayed.But Treatment of Blood stasis-removing and Phlegm eliminating joint Sulfasalazine enteric-coated tablets and Loxoprofen sodium tablets are more effective and safty than Treatment of Sulfasalazine enteric-coated tablets and Loxoprofen sodium tablets,so they are worthy of clinical application and promotion.